MDRs Jump To All-Time High; Still, FDA Says Adverse Events Underreported
This article was originally published in The Silver Sheet
Executive SummaryAlthough the number of device adverse event reports sent to FDA under the Medical Device Reporting (MDR) program has soared to its highest point ever, the agency is still concerned that events are grossly underreported.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.